Rock Springs Capital Management LP Immuneering Corp Transaction History
Rock Springs Capital Management LP
- $1.67 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding IMRX
# of Institutions
40Shares Held
4.81MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.33 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0808KShares$1.02 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD659KShares$830,3510.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$672,0380.0% of portfolio
-
Morgan Stanley New York, NY467KShares$588,7040.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $33.3M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...